Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus

被引：62

作者：

Briones, Mariele

Bajaj, Mandeep ^{[1
]}

机构：

[1] Univ Texas, Med Branch, Div Endocrinol, Galveston, TX 77555 USA

[2] Univ Texas, Med Branch, Stark Diabet Ctr, Galveston, TX 77555 USA

来源：

EXPERT OPINION ON PHARMACOTHERAPY | 2006年 / 7卷 / 08期

关键词：

exenatide; exendin-4; GLP-1; incretin; Type; 2; diabetes;

D O I：

10.1517/14656566.7.8.1055

中图分类号：

R9 [药学];

学科分类号：

1007 [药学];

摘要：

Exenatide is a glucagon-like peptide 1 receptor agonist, which has recently received FDA approval in the US for the treatment of Type 2 diabetes. Exenatide is an incretin mimetic that improves glycaemic control in patients with diabetes through acute mechanisms, such as glucose-dependent stimulation of insulin secretion, suppression of inappropriate glucagon secretion and slowing of gastric emptying, as well as chronic mechanisms that include enhancement of beta-cell mass in rodent studies and weight loss and inhibition of food intake in humans. This article reviews the mechanisms of exenatide action, as well as its efficacy in the treatment of Type 2 diabetes.

引用

页码：1055 / 1064

页数：10

共 83 条

[1]

Insulinotropic hormone glucagon-like peptide-1 differentiation of human pancreatic islet-derived progenitor cells into insulin-producing cells [J].